Literature DB >> 14531049

Dopamine transporter: basic science and human variation of a key molecule for dopaminergic function, locomotion, and parkinsonism.

George R Uhl1.   

Abstract

We review the basic science of the dopamine transporter (DAT), a key neurotransmitter for locomotor control and reward systems, including those lost or deranged in Parkinson's disease (PD). Physiology, pharmaceutical features, expression, cDNA, protein structure/function relationships, and phosphorylation and regulation are discussed. The localization of DAT provides the best marker for the integrity of just the pre-synaptic dopaminergic systems that are most affected in PD. Its function is key for the actions of several toxins that provide some of the best current models for idiopathic parkinsonism, and its variation can clearly alter movement. The wealth of information about this interesting molecule that has been developed over the last 12 years has led to increased interest in DAT among workers interested in both normal and abnormal movement. Copyright 2003 Movement Disorder Society

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14531049     DOI: 10.1002/mds.10578

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  Computational modeling of human dopamine transporter structures, mechanism and its interaction with HIV-1 transactivator of transcription.

Authors:  Yaxia Yuan; Xiaoqin Huang; Jun Zhu; Chang-Guo Zhan
Journal:  Future Med Chem       Date:  2016-10-14       Impact factor: 3.808

2.  Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Natalie Kaplan; Aya Vituri; Amos D Korczyn; Oren S Cohen; Rivka Inzelberg; Gilad Yahalom; Evgenia Kozlova; Roni Milgrom; Yael Laitman; Eitan Friedman; Saharon Rosset; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-03-15       Impact factor: 3.444

3.  Family-based study of markers at the 5'-flanking region of the human dopamine transporter gene reveals potential association with schizophrenic psychoses.

Authors:  Gerald Stöber; Julia Sprandel; Burkhard Jabs; Bruno Pfuhlmann; Kerstin Möller-Ehrlich; Michael Knapp
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-06-16       Impact factor: 5.270

Review 4.  Unbiased approaches to biomarker discovery in neurodegenerative diseases.

Authors:  Alice S Chen-Plotkin
Journal:  Neuron       Date:  2014-11-05       Impact factor: 17.173

5.  SLC6A3 is a risk factor for Parkinson's disease: a meta-analysis of sixteen years' studies.

Authors:  Desheng Zhai; Songji Li; Ying Zhao; Zhicheng Lin
Journal:  Neurosci Lett       Date:  2013-11-07       Impact factor: 3.046

6.  Manganese superoxide dismutase protects against 6-hydroxydopamine injury in mouse brains.

Authors:  Jason Callio; Tim D Oury; Charleen T Chu
Journal:  J Biol Chem       Date:  2005-03-08       Impact factor: 5.157

7.  Behavioral effects of amphetamine in streptozotocin-treated rats.

Authors:  Rajkumar J Sevak; Wouter Koek; Lynette C Daws; William Anthony Owens; Aurelio Galli; Charles P France
Journal:  Eur J Pharmacol       Date:  2007-11-28       Impact factor: 4.432

8.  Dopamine transporter genetic variants and pesticides in Parkinson's disease.

Authors:  Beate R Ritz; Angelika D Manthripragada; Sadie Costello; Sarah J Lincoln; Matthew J Farrer; Myles Cockburn; Jeff Bronstein
Journal:  Environ Health Perspect       Date:  2009-02-22       Impact factor: 9.031

Review 9.  Does the difference between physically active and couch potato lie in the dopamine system?

Authors:  Amy M Knab; J Timothy Lightfoot
Journal:  Int J Biol Sci       Date:  2010-03-09       Impact factor: 6.580

10.  How dopamine transporter interacts with dopamine: insights from molecular modeling and simulation.

Authors:  Xiaoqin Huang; Chang-Guo Zhan
Journal:  Biophys J       Date:  2007-08-17       Impact factor: 4.033

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.